

# CURRICULUM VITAE

1. Date: April 12, 2013

## I. PERSONAL

2. Name: Deborah Zipin Glick, M.D.
3. Office Phone: (954) 698-3639
4. Current Academic Rank: Assistant Professor of Clinical Medicine
5. Primary Department: Division of Hematology/Oncology
6. Citizenship: United States

## II. HIGHER EDUCATION

7. Institutions:

<b>New York Presbyterian Hospital Columbia University Campus</b> New York, NY	7/2001-6/2003 Fellow, Division of Hematology
--	---

<b>Montefiore Medical Center</b> Bronx, NY	7/1999-6/2001 Resident, Internal Medicine
---	--

<b>Montefiore Medical Center</b> Bronx, NY	7/1998-6/1999 Intern, Internal Medicine
---	--

<b>Tulane University School of Medicine</b> New Orleans, LA	8/1994-5/1998 M.D., Academic Scholarship
--	---

<b>University of Pennsylvania</b> Philadelphia, PA	9/1990-5/1994 B.A., Cum Laude & Phi Beta Kappa
---	--

<b>Hillel Academy High School</b> Dayton, OH	8/1986-6/1990 Valedictorian
---	--------------------------------

08. Certification:

Board Certified in Hematology	11/2003 (Recert 2012)
Board Certified in Internal Medicine	2001-2011

09. Licensure:

State of Florida #ME 87155	2003-present
State of New York #216145	1999-2003

### III. EXPERIENCE

#### 10. Academic:

<b>University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center</b>	Deerfield Beach, FL
-Interim Medical Director	9/2006-5/2007
-Medical Director	6/2007-8/2010
-Assistant Professor of Clinical Medicine	9/2006-present
<b>Florida Atlantic University Charles E. Schmidt College of Biomedical Science</b>	Boca Raton, FL
-Affiliate Clinical Assistant Professor	2005-present

#### 11. Hospital Appointments:

<b>Jackson Memorial Hospital</b> Miami, FL	2007-2012
<b>University of Miami Medical Center</b> Miami, FL	2006-present
<b>Boca Raton Community Hospital</b> Boca Raton, FL	2003-present
<b>Delray Medical Center</b> Delray Beach, FL	2003-2006
<b>Pinecrest Rehabilitation Hospital</b> Delray Beach, FL	2003-2006

#### 12. Non-Academic:

<b>The Center for Hematology-Oncology</b> -Clinical Hematologist	Boca Raton & Delray Beach, FL 2003-2006
---	--

### IV. PUBLICATIONS

Bayraktar UD, Barker J, Pereira D, Glick DZ, Byrne Jr GE, Escalon MP. *An unusual presentation of extramedullary biphenotypic lymphoblastic lymphoma*, Am J Hematology, 84(9):616-7, 2009.

Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, Tierstan A, Nichols G, Troxel A, Hesdorffer CS. *Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk breast cancer*, Bone Marrow Transplant, 40(3):267-72, 2007.

Zipin D, Savage DG. *Reduced dose Imatinib Mesylate therapy for chronic myeloid leukemia*, Leuk. Lymphoma, 45(11):2363-64, 2004.

Savage DG, Zipin D, Bhagat G, Alobeid B. *Hemophagocytic, non-secretory multiple myeloma*, Leuk. Lymphoma, 45(5):1061-64, 2004.

Foundas, AL, Zipin D, and Browning CA. *Age-related changes of the insular cortex and lateral ventricles: conventional MRI volumetric measures*, J. Neuroimaging, 8(4): 216-21, 1998.

## V. PROFESSIONAL

### 15. Research interests:

#### **Principal Investigator**

- 2010 ECOG E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia. (SCCC 2009028)
- 2005 Decitabine in High Risk Myelodysplastic Syndrome
- 2005 Doxil/Caelyx and Velcade or Velcade Monotherapy for Relapsed Multiple Myeloma

#### **Clinical Investigator**

- 2011 Phase 1B open-label study of the safety and clinical activity of Crizotinib (PF-02341066) in tumors with genetic events involving the Anaplastic Lymphoma Kinase (ALK) gene locus.
- 2011 Phase II study to evaluate Fenofibrate therapy in Multiple Myeloma patients.
- 2010 Prospective. Longitudinal, Multinational Registry of patients with newly diagnosed peripheral T-Cell Lymphoma.
- 2010 Phase III Rituxan/BEAM vs. BEXXAR/BEAM with autologous hematopoietic stem cell transplantation for persistent or relapsed chemotherapy sensitive diffuse Large B-Cell Non-Hodgkin's Lymphoma.
- 2009 A randomized two-arm, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 70mg twice daily or 140mg once daily in subjects with chronic Myeloid Leukemia in accelerated phase or in Myeloid or Lymphoid Blast phase or with Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to Imatinib Mesylate.
- 2009 A phase 2 trial of MLN8237, an oral aurora a Kinase Inhibitor, in adult patients with aggressive Non-Hodgkin's Lymphoma.
- 2006 ECOG E2805: A randomized, double-blinded phase III trial of adjuvant Sunitinib versus Sorafenib versus placebo in patients with resected Renal Cell Carcinoma
- 2006 GOG 0218: A phase III trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab followed by placebo, versus Carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women with newly diagnosed, previously untreated, suboptimal advanced staged epithelial ovarian and primary peritoneal cancer.
- 2006 A phase II trial of combination Bortezomib and Ritumaxib as front-line therapy for low-grade Non-Hodgkin's Lymphoma.

- 2006 Phase II study to establish gene expression models predicting survival of diffuse Large B-Cell Lymphoma patients treated with R-CHOP.
- 2006 Phase II study of Ibritumomab Tiuxetan (zevalin) in patients with previously untreated marginal zone Lymphoma.
- 2005 ECOG S0325: A phase IIB study of molecular responses to Imatinib at standard or increased doses, or Dasatinib (BMS-354825) (NSC-732517) for previously untreated patients with chronic Myelogenous Leukemia (CML) in chronic phase. (SCCC 2005012)
- 2005 Thal/Dex vs. Doxil + Thal/Dex in Multiple Myeloma
- 2004 Favld Vaccine and GM-CSF vs. Placebo and GM-CSF for NHL
- 2004 Phase II Study of Rituximab in combination with Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in patients with previously untreated mentle cell lymphoma.

**Research Assistant**

- 1996 Anne Foundas, M.D., Tulane University School of Medicine, Department of Neurology  
-Elucidated the changes that occur in the CSF-insula cortex with age.
- 1992-1994 W. Gillies McKenna, M.D., Ph.D., University of Pennsylvania School of Medicine, Division of Radiation and Oncology  
-Determined the DNA sequence of the hamster cyclin A gene.

12. Professional Organizations:

American Society Hematology

VI. TEACHING

13. Teaching specialization:

- |   |  |
|---|--|
| <p><b>University of Miami Miller School of Medicine<br/>at Florida Atlantic University</b><br/>-M2 lecture, <i>Hypercoagulability</i><br/>-M2 lecture, <i>Disorders of Hemostasis</i></p> | <p>Boca Raton, FL<br/><br/>2005<br/>2005</p> |
| <p><b>UM/Sylvester at Deerfield Beach</b><br/>-Conversations About Cancer Program lecture,<br/><i>New Treatment Options in Myelodysplastic Syndromes</i></p>                              | <p>Deerfield Beach, FL<br/>2007</p>          |
| <p><b>University of Miami Miller School of Medicine<br/>at Florida Atlantic University</b><br/>-M2 lecture, <i>Anemia's of Blood Loss and Diminished Erythropoeisis</i></p>               | <p>Boca Raton, FL<br/><br/>2010</p>          |

